Research Article

circFAM160A2 Promotes Mitochondrial Stabilization and Apoptosis Reduction in Osteoarthritis Chondrocytes by Targeting miR-505-3p and SIRT3

Jiapeng Bao, Changjian Lin, Xing Zhou, Diana Ma, Lujie Ge, Kai Xu, Safwat Adel Abdo Moqbel, Yuzhe He, Chiyuan Ma, Jisheng Ran, and Lidong Wu

1Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, China
2Orthopedics Research Institute of Zhejiang University, Hangzhou City, Zhejiang Province, China
3Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou City, Zhejiang Province, China

Correspondence should be addressed to Lidong Wu; wulidong@zju.edu.cn

Received 11 July 2021; Revised 5 September 2021; Accepted 7 September 2021; Published 4 October 2021

Academic Editor: Ralf Braun

Copyright © 2021 Jiapeng Bao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competitive endogenous RNAs (ceRNAs), as a newly identified regulating mechanism, have been demonstrated to play a crucial role in various human diseases. An increasing number of recent studies have revealed that circular RNAs (circRNAs) can function as ceRNAs. However, little is known about the role of circFAM160A2 in the pathological process of osteoarthritis (OA). This study is the first to examine the crucial role of the circFAM160A2-miR-505-3p-SIRT3 axis in osteoarthritis progression. miR-505-3p was selected from the interaction of a microRNA (miRNA) microarray comparing chondrocytes in OA and normal conditions and prediction results from TargetScan. RT-qPCR was performed to assess the expression of circFAM160A2, miR-505-3p, and SIRT3. A dual luciferase assay was used to validate the binding of circFAM160A2, miR-505-3p, and SIRT3. We used lentivirus and adeno-associated virus to establish in vitro and in vivo overexpression models. Western blotting, apoptosis assay, ROS detection assay, Safranin O staining, and CCK-8 assay were employed to assess the role of circFAM160A2, miR-505-3p, and SIRT3. We found that miR-505-3p was upregulated in OA. While overexpression of circFAM160A2 decreased the production of extracellular matrix (ECM) degrading enzymes and ameliorated chondrocyte apoptosis and mitochondrial dysfunction, inhibition of miR-505-3p could reverse the protective effect of circFAM160A2 on the OA phenotype both in vitro and in vivo. In conclusion, circFAM160A2 can promote mitochondrial stabilization and apoptosis reduction in OA chondrocytes by targeting miR-505-3p and SIRT3, which might be a potential therapeutic target for OA therapy.

1. Introduction

Osteoarthritis (OA) is the most common joint disorder, leading to a massive socioeconomic cost as well as causing pain or even disability to the estimated 10% of men and 18% of women over 60 years of age affected worldwide [1, 2]. Researchers have reported that OA is characterized by progressive articular cartilage loss, osteophyte formation, synovial inflammation [3], and impairment of mitochondrial function [4]. Nevertheless, treatment is limited to pain management or joint replacement for end-stage disease [5], as the underlying molecular mechanism driving OA pathology remains elusive.

Mitochondrial dysfunction is a hallmark of OA and has recently drawn particular attention [6]. The sirtuin (SIRT) family, a class of evolutionarily conserved NAD+–dependent deacetylase proteins, contributes to the regulation of energy balance [7]. Recent insights have revealed that among the
sirtuin family members, SIRT3 plays a chondroprotective role in OA by maintaining mitochondrial homeostasis [8] and preserving mitochondrial DNA integrity and function [9]. However, the upstream regulatory mechanism of SIRT3 has not yet been fully elucidated.

Circular RNAs (circRNAs) are a special subclass of endogenous noncoding RNAs produced by a noncanonical splicing event called backsplicing [10]. They are highly stable because of their covalently closed ring structure, and some of them are evolutionarily conserved [11]. Furthermore, previous studies reported that circRNAs can exert their biological function as microRNA (miRNA) sponges [12, 13] and RNA-binding protein sponges [14] and more controversially, through protein translation [15]. The emerging roles of RNA–RNA crosstalk are further confirmed as our knowledge of noncoding RNAs has expanded. However, little is known about the functional regulation of competing endogenous RNAs on SIRT3 in OA.

In this study, we aimed to discern the potential upstream regulatory mechanism of SIRT3 in OA pathological progression using RNA deep-sequencing technology and substantial experiments in vitro and in vivo.

2. Materials and Methods

2.1. Ethical Approval. All animal experiments were approved by the Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine and carried out under the guidelines of the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.

2.2. Clinical Samples. OA tissue samples and normal tissue samples from 5 OA patients and 5 femoral neck fracture patients, respectively, were collected from the surgical specimen archives of Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, China. All the procedures were approved by the Institutional Review Board of the Second Affiliated Hospital of Zhejiang University School of Medicine. We have obtained written informed consent from all study participants. All of the procedures were performed in accordance with the Declaration of Helsinki and relevant policies in China.

2.3. Reagents. Recombinant rat IL-1β was purchased from R&D Systems, Abingdon, UK. Dulbecco’s modified Eagle’s medium (DMEM), penicillin/streptomycin, fetal bovine serum (FBS), and 0.25% trypsin were obtained from Gibco BRL, Grand Island, NY, USA. Collagenase II was purchased from Sigma-Aldrich, St. Louis, MO, USA.

2.4. Luciferase Assay. To confirm the database binding prediction that the 568th to 575th bases of the SIRT3 3′ untranslated region (UTR) was specifically bound by miR-505-3p and miR-505-3p was specifically bound by circFAM160A2, the Dual Luciferase® Reporter Assay System (Promega, E1910, USA) was performed according to the manufacturer’s instruction. Lipo3000 (Thermo Fisher, L3000150, USA) was used for transfection.

2.5. Lentiviral Overexpression Model. We used lentivirus to establish overexpression models of SIRT3, miR-505-3p, and circFAM160A2. The lentivirus circFAM160A2 was constructed and packaged by Hanbio (Shanghai, China). The lentivirus SIRT3 and miR-505-3p were constructed and packaged by (Genechem, Shanghai, China).

2.6. Bioinformatics Analysis. The miRNA targets of SIRT3 were predicted using the bioinformatics database TargetScan (http://www.targetscan.org/). We predicted the circRNA binding sites of miR-505-3p using the database miRanda (http://www.microrna.org). After selecting the results with a high level of evidence based on their indexes, we performed the overlapping interactions with a Venn diagram constructed by a web-based tool (http://bioinformatics.psb.ugent.be/webtools/Venn/).

2.7. Western Blotting. The adherent cells were washed three times with PBS and then detached with a cell scraper. Thereafter, the harvested cells were lysed in RIPA Lysis Buffer (P0013B, Beyotime, China) containing a protease inhibitor cocktail (P1005, Beyotime, China), a protein phosphatase inhibitor (P1260, Solarbio Science & Technology, Beijing, China), and a PMSF (A610425-0005, Sangon Biotech, Shanghai, China) on ice for 30 min. The Bradford Protein Assay Kit (P0006, Beyotime, China) was conducted according to the manufacturer’s instruction to measure the protein concentrations. An aliquot of 15 μg of total proteins from each sample was separated by SDS-PAGE gels at 100 V for 1.5 h and transferred onto polyvinylidene difluoride (PVDF) membranes (IPVH00010, Millipore, Billerica, MA, USA) at 300 mA for 1 h. Subsequently, the membranes were blocked for 2 h with 5% BSA (A600903, Sangon Biotech, Shanghai, China) at room temperature. After washing three times with TBST, the membranes were incubated with primary antibodies against GAPDH (1 : 1000, ab181602, Abcam), SIRT3 (1 : 500, ab118334, Abcam), MMP13 (1 : 1000, ab84594, Abcam), ADAMTS4 (1 : 500, ab185722, Abcam), collagen II (1 : 1000, NB600-844, RD), Bax (1 : 1000, ab32503, Abcam), Bcl-2 (1 : 500, ab194583, Abcam), and procaspase 3 (1 : 1000, ab90437, Abcam) overnight at 4°C. The next day, the membranes were washed three times with TBST and were incubated with horseradish peroxidase- (HRP-) conjugated goat anti-mouse and anti-mouse secondary antibodies (31160, 31210; 1 : 5000, Thermo Fisher, USA) at room temperature. After washing three times with TBST again, the membranes were measured by using the SuperSignal® West Dura Extended Duration Substrate (34075, Thermo Fisher, USA). ImageJ software was performed to quantify the intensity of each band.

2.8. RNA Extraction and qRT-PCR. Total RNA was extracted using the Rapid Extraction kit for animal total RNA (GK3016, Generay Biotech, Hangzhou, China) while miRNA isolation was performed by the PureLink® miRNA Isolation Kit (K1570-01, Thermo Fisher, USA) according to the manufacturer’s instructions. HiScript Q RT SuperMix for qPCR (R222-01, Vazyme, Nanjing, China) was used to reverse-transcribe the mRNA/circRNA to...
DNA templates. miRNA was reverse-transcribed by using SuperScript™ III Reverse Transcriptase (18080085, Thermo Fisher, USA). Quantitative altimeter PCR was performed with PowerUp™ SYBR™ Green Master Mix (A25779, Applied Biosystems, USA) with the CFX Connect Real-Time System (BIO-RAD, USA). For the circRNA, specific divergent primers crossing the back-spliced junction were designed. All reactions were analyzed in triplicate. Housekeeping genes U6 and actin were used to normalize the analysis of miRNA and mRNA/circRNA, respectively. The relative miRNA/mRNA/circRNA expression levels were assessed using the 2^ΔΔCT method. All the primers used in this study are listed in Supplementary Table S1.

2.9. Flow Cytometry Assays. To estimate the apoptosis of pretreated cells, the Annexin V-FITC/PI apoptosis detection kit (KGA108, KeyGEN BioTECH, China) was used according to the manufacturer’s instructions. Apoptosis was detected with a flow cytometer (Cytek, DXPSF13, USA).

For mitochondrial ROS analysis, H2DCFDA (65480, MCE, China) was used to detect mitochondrial ROS in the cells as the manufacturer’s instruction described. In brief, cells were cultured with DCFH-DA at 37°C for 30 min. After the samples were washed three times with PBS, mitochondrial ROS was measured using a flow cytometer mentioned above.

2.10. Animal Model. The anterior cruciate ligament transsection (ACL transect) model is a classic model mimicking the condition of OA [16, 17]. Since circFAM160A2 manifested an anti-OA role in vitro, we proceeded to further investigate the potential role of circFAM160A2 in OA in vivo. In our study, twenty-four-week-old male C57BL/6j (wild type) were divided into four groups and used for the experiments. The adeno-associated virus circFAM160A2 wt and mut were constructed and packaged by Hanbio (Shanghai, China). We injected adeno-associated virus-overexpression circFAM160A2 particles (AAV-circ) and adeno-associated virus-overexpression circFAM160A2 mut particles (AAV-mut) into the knee joints of mice with sham surgery or OA induced by ACL transect surgery. After four weeks of treatment, mice were executed and treated as our previous study [18].

2.11. Statistical Analysis. All quantitative data are presented as the mean ± SDs. One-way ANOVA with subsequent post hoc Tukey’s test was used for multiple comparisons. The value of P < 0.05 was considered to indicate significant differences.

3. Results

3.1. miR-505-3p Is Upregulated in OA Tissue and Directly Targets SIRT3. The heat map of the microarray expression profile shows the differential expression of all miRNAs (Figure 1(a)). Four candidate miRNAs—hsa-miR-421, hsa-miR-505-3p, hsa-miR-186-5p, and hsa-miR-1301-3p—were selected from the TargetScan database according to their scores (Figure 1(b)). The expression levels of three miRNAs were significantly higher than those in the controls (Figure 1(c)). However, hsa-miR-505-3p had a higher ratio of expression in OA to expression in the control group than the other miRNAs and was consequently studied in subsequent experiments. The 568th to 575th bases of the SIRT3 3′ untranslated region (UTR) was specifically bound by miR-505-3p on an 8mer binding target site type, according to the database (Figure 1(d)). Reduced luciferase activity of the SIRT3 3′-UTR was observed under miR-505-3p overexpression. In contrast, luciferase activity was much higher when a mutated form of SIRT3 3′-UTR was used (Figure 1(e)). Most efficient miRNAs function posttranscriptionally by base-pairing to the mRNA 3′-UTR to inhibit protein synthesis [19, 20]. The overexpression of miR-505-3p downregulated SIRT3 mRNA levels (Figure 1(f)).

3.2. Overexpression of miR-505-3p Contributes to ECM Degradation and Chondrocyte Apoptosis. SIRT3 was also observed to be downregulated at the protein level in the LV-miR group compared with the control and lentivirus vector groups. After overexpression of miR-505-3p using LV-miR, both matrix metalloproteinase 3 (MMP3) and cyclooxygenase 2 (COX2) were overexpressed, while a reduction in chondrocyte-specific protein type II collagen (COL2) expression was observed relative to that in the control (Figures 2(a) and 2(b)). CCK-8 results indicated that under 24-hour treatment, the lentivirus vector inhibited chondrocyte viability down to 95% with no significance, whereas overexpression of miR-505-3p exacerbated the inhibitory effect and significantly decreased the chondrocyte viability to 91%. Collectively, these data suggest that overexpression of miR-505-3p accelerates OA progression in chondrocytes.

3.3. Upregulation of SIRT3 Rescues miR-505-3p-Induced Mitochondrial Dysfunction. In our previous review [21], we systematically elaborated the vital role of SIRT3 in mitochondrial homeostasis in OA. Since miR-505-3p was able to modulate SIRT3 expression, we considered that its role in mitochondrial metabolism and function was worthy of further research. A previous study showed that SIRT3 is able to protect mitochondria from oxidative damage by deacetylating forkhead box O3α (FOXO3α) [22]. The same elevated protein expression level of FOXO3α was observed in the present study (Figures 2(d) and 2(e)). Mitochondrial fission and fusion are competing processes contributing to changes in mitochondrial morphology and metabolism. Mitofusin 2 (MFFN2) is a key regulator of mitochondrial fusion, while mitochondrial fission factor (MFF) is required for mitochondrial fission [23, 24]. Western blot results showed that overexpression of miR-505-3p upregulated MFF and downregulated MFFN2, while SIRT3 overexpression reversed this effect (Figures 2(d) and 2(e)). The altered expression of MFF and MFFN2 indicated that SIRT3 downregulation led to a shift in mitochondrial dynamics from fusion to fission. Mitochondrial fusion is negatively associated with reactive oxygen species (ROS) production [25], which is consistent with our subsequent ROS detection experiment using oxidized DCFDA and flow cytometry. Mitochondrial dysfunction occurs as a result of disruption of fusion, while ROS is the byproduct of normal mitochondrial metabolism and homeostasis [26]. Jones proposed that excessive levels of...
(a) Complementary miRNAs identified by RNA-seq and TargetScan.

(b) Venn diagram showing the overlap of miRNAs between RNA-seq and TargetScan.

(c) Bar graph showing the relative normalized expression of specific miRNAs in control and OA groups.

(d) Alignment of SIRT3 and SIRT3 mut sequences.

**Figure 1:** Continued.
ROS cause cellular damage and subsequently contribute to the progression of age-related diseases, such as OA [27]. Overexpression of SIRT3 rescued the increase in ROS induced by overexpression of miR-505-3p (Figure 2(g)). These results support our hypothesis that upregulation of SIRT3 could rescue miR-505-3p-induced mitochondrial dysfunction.

3.4. Upregulation of SIRT3 Reverses miR-505-3p-Induced Chondrocyte Apoptosis. As chondrocytes are the major cell type forming cartilage, their gradual apoptosis is a hallmark of OA pathogenesis and progression [28]. As the apoptosis assessment results show (Figures 2(d) and 2(e)), in the LV-miR group, the expression levels of proapoptotic proteins caspase 3 and Bax were significantly increased, whereas the expression of antiapoptotic protein, Bcl-2, was markedly decreased, when compared to that in the control. Meanwhile, a larger number of apoptotic cells were detected in the LV-miR group than in the control (Figure 2(f)). All of these proapoptosis effects could be rescued by overexpression of SIRT3.

3.5. circFAM160A2 Functions as an Efficient miR-505-3p Sponge in OA. Recent studies have shown that several efficient circRNAs function as miRNA sponges to indirectly regulate the expression of target genes [13, 29]. miRanda analysis results are shown in Supplementary Table S2. The top three circRNAs, hsa_circ_0020990, hsa_circ_0075423, and hsa_circ_0084161, were selected for further investigation. Significant reductions in circRNA expression levels were observed in the OA tissues versus normal tissues for the three circRNAs. Interestingly, the expression of hsa_circ_0020990 in OA tissues was undetectable despite several optimization approaches (Figure 3(a)). Since its expression was detected in normal samples, it would not be unreasonable to assume that the actual expression of hsa_circ_0020990 simply falls below the RT-qPCR detection threshold. Therefore, hsa_circ_0020990 (circFAM160A2) was chosen for further study. The promising binding sites of circFAM160A2 (wt)-miR-505-3p are shown in Figure 3(b). We found that the luciferase activity of the miR-NC reporters was significantly higher than that of the miR-505-3p-transfected chondrocyte reporters. In contrast, the reporter containing the circFAM160A2 mut had the strongest luciferase activity, indicating that miR-505-3p can directly bind to circFAM160A2 (Figure 3(c)). To confirm the circFAM160A2-miR-505-3p-SIRT3 axis in chondrocytes, we design six groups: NC, LV-circFAM160A2, LV-circ vector, LV-miR-505-3p, LV-miR mut, and LV-circFAM160A2+LV-miR-505-3p. Western blot of SIRT3 results in circFAM160A2 overexpression models showing that overexpression of circFAM160A2 could upregulate the protein level of SIRT3, whereas using LV-miR to overexpress miR-505-3p would inhibit the impact of circFAM160A2 (Figure 3(d)). These results demonstrate that circFAM160A2 modulates the expression of SIRT3 by targeting miR-505-3p.

3.6. circFAM160A2 Attenuates OA-Related ECM Degradation and Chondrocyte Apoptosis In Vitro. The miR-505-3p expression level was elevated in the IL-1β group, whereas using LV-circ significantly inhibited this elevation (Figure 4(a)). Meanwhile, compared with the IL-1β stimulated group, SIRT3, COL2, and Bcl-2 were significantly increased, while Bax and extracellular matrix (ECM) degrading associated proteins...
COL2  COX2  SIRT3  MMP3  GAPDH
NC  LV-miR  Vector

Relative normalized expression

(a)

NC  LV-miR  Vector

(b)

Relative normalized expression

(c)

NC  OE-miR  Vector

(d)

Figure 2: Continued.
MMP13 and ADAMTS4 decreased in the LV-circ group (Figures 4(b) and 4(c)). A reduction in the number of apoptotic cells was also observed in the LV-circ group when compared to that in the control. Collectively, circFAM160A2 was demonstrated to play a positive role in ameliorating the progression of OA in vitro.
3.7. *circFAM160A2* Alleviates OA Progression In Vivo. The effects of *circFAM160A2* on miR-505-3p in vivo were similar to its in vitro effects (Figure 5(a)). The protein levels of MMP13 and proapoptotic proteins caspase 3 and Bax significantly decreased, while SIRT3 and COL2 markedly increased after treatment with *circFAM160A2* (Figures 5(b) and 5(c)). Safranin O staining showed that compared to the AAV-mut group, the AAV-circ group had less cartilage destruction (Figure 5(d)). All of the in vivo results supported the protective role of *circFAM160A2* in OA progression.

4. Discussion

OA is a prevalent degenerative joint disease whose etiology spans several disciplines, including biomechanics and bio-chemistry, and can involve multiple cellular and molecular pathways [30]. There have been some efforts to improve the understanding of OA causation and pathogenesis which may contribute to the identification of patients at greatest risk of disease and facilitate early diagnosis. However, for patients with clinical OA symptoms, most therapies are limited to pain management and joint replacement surgery. Until recently, no new therapeutic inquiries have been approved [2]. Elucidating the precise mechanism of OA progression for the development of improved therapies is a pressing and urgent task for researchers.

The sirtuin (SIRT) family, a class of evolutionarily conserved NAD⁺-dependent deacetylase proteins, contributes to the regulation of energy balance [7]. Among them, SIRT3 is a crucial member in regulating mitochondrial biogenesis and participates in diverse physiological and pathological...
**Figure 4: Continued.**

(a) Relative ADAMTS4 protein expression

(b) Relative SIRT3 protein expression

(c) Relative Col2 protein expression

(d) Relative Bax protein expression

(e) Relative Bcl-2 protein expression

(f) Relative GAPDH protein expression

SIRT3, MMP13, ADAMTS 4, Col2, Bax, Bcl-2, GAPDH
processes. Recently, we found that SIRT3 could ameliorate osteoarthritis via regulating chondrocyte autophagy and apoptosis through the PI3K/Akt/mTOR pathway [37]. Besides, our previous study elaborated the vital role of SIRT3 in mitochondrial homeostasis in OA [21], and Wang et al. and Chen et al. further confirmed the protective role of SIRT3 in this condition [8, 9]. In the present study, diverse experiments collectively verified that SIRT3 ameliorated osteoarthritis progression via reducing chondrocyte apoptosis as well as improving mitochondrial dysfunction.

To further study the upstream regulating mechanism of SIRT3, we designed a series of experiments to determine the specific miRNA and circRNA that modulate the expression of SIRT3. Due to considerable progress in the field, the mechanisms by which miRNAs function as repressors of protein production, by inhibiting translation or destabilizing the mRNAs, are relatively well understood [31, 32]. The competitive endogenous RNA (ceRNA) hypothesis postulates that any RNA transcript that harbors miRNA-response elements (MRE) is able to sequester miRNAs from other targets sharing the same MREs [33], thus modulating related mRNA or protein expression. Recently, an increasing number of studies have indicated that circRNAs can act as ceRNAs via sponging miRNAs. Chen et al. reported that reference circRAPGEF5 could sponge miR-27a-3p, thereby inhibiting the growth and metastasis of renal cell carcinoma [34], while Sang et al. demonstrated that circRNA_0025202 could sponge miR-182-5p to regulate breast cancer progression [35]. In the OA research field, some researchers have also revealed that circRNAs act as miRNA sponges [13, 36]. However, most studies began with RNA-seq to identify differentially expressed circRNAs and subsequently investigated their binding miRNAs and potential roles in diseases. According to the ceRNA hypothesis, using databases and RNA-seq techniques to seek the miRNAs that inhibit a particular mRNA, and then finding the upstream circRNAs sponging the selected miRNA, is also a valid research strategy. Therefore, based on our previous work, we decided to investigate the potential miRNAs and circRNAs acting as ceRNA networks regulating SIRT3 directly or indirectly.

According to the ceRNA hypothesis, since SIRT3 is downregulated in OA, the miRNA and circRNA we looked for should be upregulated and downregulated, respectively. Thus, we used our upregulated miRNAs in OA from our RNA-seq results to combine with the TargetScan database to identify miRNAs that promisingly inhibit SIRT3 in OA. The top four candidate miRNAs were selected from the intersection. Based on their differential expression in OA
Figure 5: circFAM160A2 alleviates OA in vivo. (a) ACLT-induced OA mice were injected with AAV negative control, wt AAV circFAM160A2, or mut AAV circFAM160A2. The relative expression of miR-505-3p was detected using qRT-PCR (N = 3). (b, c) The relative expression of SIRT3, procaspase 3, Bax, MMP13, COL2, and GAPDH was detected using WB (N = 3). (d) Typical images of Safranin O/fast green staining of the cartilage in the indicated groups at six weeks after surgery (data are presented as the mean ± SD, *P < 0.05 vs. control, #P < 0.05 vs. ACLT group by Student’s t-test).
In conclusion, our study demonstrated that circFAM160A2 can function as a ceRNA to sequester miR-505-3p, thereby upregulating the expression of SIRT3. Moreover, circFAM160A2 attenuates the progression of OA by stabilizing mitochondria and ameliorating apoptosis in osteoarthritis chondrocytes both in vitro and in vivo. This study suggests a potential therapeutic target for OA treatment.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Disclosure

This manuscript has been presented as a preprint [38] in the following link “https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3817430”.

Conflicts of Interest

All authors have no conflicts of interest to declare.

Authors’ Contributions

Jiapeng Bao and Changjian Lin contributed equally to this work.

Acknowledgments

This study was funded by the National Natural Science Foundation of China (Nos. 81401824, 81871793, and 81572173).

Supplementary Materials

All the primers used in this study are listed in Supplementary Table S1. miRanda analysis results of putative upstream targets of miR-505-3p are shown in Supplementary Table S2. (Supplementary Materials)

References

[1] A. D. Woolf and B. Pfleger, “Burden of major musculoskeletal conditions,” Bulletin of the World Health Organization, vol. 81, no. 9, pp. 646–656, 2003.
[2] S. Glynn-Jones, A. J. R. Palmer, R. Agricola et al., “Osteoarthritis,” Lancet, vol. 386, pp. 376–387, 2015.
[3] R. F. Loeser, S. R. Goldring, C. R. Scanzello, and M. B. Goldring, “Osteoarthritis: a disease of the joint as an organ,” Arthritis and Rheumatism, vol. 64, pp. 1697–1707, 2012.
[4] E. Maneiro, M. A. Martin, M. C. de Andres et al., “Mitochondrial respiratory activity is altered in osteoarthritic human articular chondrocytes,” Arthritis and Rheumatism, vol. 48, pp. 700–708, 2003.
[5] L. A. Mandl, “Osteoarthritis year in review 2018: clinical,” Osteoarthritis and Cartilage, vol. 27, pp. 359–364, 2019.
[6] R. F. Loeser, J. A. Collins, and B. O. Diekman, "Ageing and the pathogenesis of osteoarthritis," *Nature Reviews Rheumatology*, vol. 12, pp. 412–420, 2016.

[7] L. Mouchiroud, R. H. Houtkooper, N. Moullan et al., “The NAD+/Sirtuin pathway modulates longevity through activation of mitochondrial UPAR and FOXO signaling,” *Cell*, vol. 154, pp. 430–441, 2013.

[8] J. Wang, K. Wang, C. Huang et al., “SIRT3 activation by dihydroxyricetin suppresses chondrocytes degeneration via maintaining mitochondrial homeostasis,” *International Journal of Biological Sciences*, vol. 14, no. 13, pp. 1873–1882, 2018.

[9] L. Y. Chen, Y. Wang, R. Terkeltaub, and R. Liu-Bryan, “Activation of AMPK-SIRT3 signaling is chondroprotective by preserving mitochondrial DNA integrity and function,” *Osteoarthritis and Cartilage*, vol. 26, pp. 1539–1550, 2018.

[10] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbe-R. F. Loeser, J. A. Collins, and B. O. Diekman, “A. Isbatan, and M. P. Gupta, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," *Physiological Reviews*, vol. 94, pp. 909–950, 2014.

[11] L. Mouchiroud, R. H. Houtkooper, N. Moullan et al., “Mitochondrial dynamics and metabolic regulation,” *Molecular Therapy*, vol. 77, 2020.

[12] L. Y. Chen, Y. Wang, R. Terkeltaub, and R. Liu-Bryan, “Activation of AMPK-SIRT3 signaling is chondroprotective by preserving mitochondrial DNA integrity and function,” *Osteoarthritis and Cartilage*, vol. 26, pp. 1539–1550, 2018.

[13] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbe-R. F. Loeser, J. A. Collins, and B. O. Diekman, “A. Isbatan, and M. P. Gupta, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," *Physiological Reviews*, vol. 94, pp. 909–950, 2014.

[14] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbe-R. F. Loeser, J. A. Collins, and B. O. Diekman, “A. Isbatan, and M. P. Gupta, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," *Physiological Reviews*, vol. 94, pp. 909–950, 2014.

[15] L. Y. Chen, Y. Wang, R. Terkeltaub, and R. Liu-Bryan, “Activation of AMPK-SIRT3 signaling is chondroprotective by preserving mitochondrial DNA integrity and function,” *Osteoarthritis and Cartilage*, vol. 26, pp. 1539–1550, 2018.

[16] L. Mouchiroud, R. H. Houtkooper, N. Moullan et al., “The NAD+/Sirtuin pathway modulates longevity through activation of mitochondrial UPAR and FOXO signaling,” *Cell*, vol. 154, pp. 430–441, 2013.

[17] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbe-R. F. Loeser, J. A. Collins, and B. O. Diekman, “A. Isbatan, and M. P. Gupta, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," *Physiological Reviews*, vol. 94, pp. 909–950, 2014.

[18] L. Mouchiroud, R. H. Houtkooper, N. Moullan et al., “The NAD+/Sirtuin pathway modulates longevity through activation of mitochondrial UPAR and FOXO signaling,” *Cell*, vol. 154, pp. 430–441, 2013.

[19] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbe-R. F. Loeser, J. A. Collins, and B. O. Diekman, “A. Isbatan, and M. P. Gupta, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," *Physiological Reviews*, vol. 94, pp. 909–950, 2014.

[20] L. Y. Chen, Y. Wang, R. Terkeltaub, and R. Liu-Bryan, “Activation of AMPK-SIRT3 signaling is chondroprotective by preserving mitochondrial DNA integrity and function,” *Osteoarthritis and Cartilage*, vol. 26, pp. 1539–1550, 2018.

[21] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbe-R. F. Loeser, J. A. Collins, and B. O. Diekman, “A. Isbatan, and M. P. Gupta, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," *Physiological Reviews*, vol. 94, pp. 909–950, 2014.

[22] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbe-R. F. Loeser, J. A. Collins, and B. O. Diekman, “A. Isbatan, and M. P. Gupta, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," *Physiological Reviews*, vol. 94, pp. 909–950, 2014.

[23] L. Mouchiroud, R. H. Houtkooper, N. Moullan et al., “The NAD+/Sirtuin pathway modulates longevity through activation of mitochondrial UPAR and FOXO signaling,” *Cell*, vol. 154, pp. 430–441, 2013.

[24] L. Y. Chen, Y. Wang, R. Terkeltaub, and R. Liu-Bryan, “Activation of AMPK-SIRT3 signaling is chondroprotective by preserving mitochondrial DNA integrity and function,” *Osteoarthritis and Cartilage*, vol. 26, pp. 1539–1550, 2018.

[25] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbe-R. F. Loeser, J. A. Collins, and B. O. Diekman, “A. Isbatan, and M. P. Gupta, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," *Physiological Reviews*, vol. 94, pp. 909–950, 2014.

[26] L. Mouchiroud, R. H. Houtkooper, N. Moullan et al., “The NAD+/Sirtuin pathway modulates longevity through activation of mitochondrial UPAR and FOXO signaling,” *Cell*, vol. 154, pp. 430–441, 2013.

[27] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbe-R. F. Loeser, J. A. Collins, and B. O. Diekman, “A. Isbatan, and M. P. Gupta, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," *Physiological Reviews*, vol. 94, pp. 909–950, 2014.

[28] L. Y. Chen, Y. Wang, R. Terkeltaub, and R. Liu-Bryan, “Activation of AMPK-SIRT3 signaling is chondroprotective by preserving mitochondrial DNA integrity and function,” *Osteoarthritis and Cartilage*, vol. 26, pp. 1539–1550, 2018.

[29] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbe-R. F. Loeser, J. A. Collins, and B. O. Diekman, “A. Isbatan, and M. P. Gupta, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," *Physiological Reviews*, vol. 94, pp. 909–950, 2014.

[30] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbe-R. F. Loeser, J. A. Collins, and B. O. Diekman, “A. Isbatan, and M. P. Gupta, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," *Physiological Reviews*, vol. 94, pp. 909–950, 2014.